Stock listing

NYSE American:AEON AEON Biopharma, Inc. Stock

Home listing (NYSE American) of AEON Biopharma, Inc.

Follow AEON Biopharma, Inc. into a list and get an email when it puts out news.

Share price · AMEX:AEON

$0.123 USD -0.001 (-1.0%)

Close on Nov 20, 2026

Past year -85.0% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.122 – $0.135 USDNov 20, 2026
Volume
1.17M sharesNov 20, 2026
Market cap
$7.27M USDAt the close on Nov 20, 2026 · price × 59.08M shares outstanding
52-week range
$0.107 – $1.450 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$2.05M USDMedian day 956,900 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
AEON Biopharma, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NYSE American:AEON · Home$0.123 USD-0.001 (-1.0%)1,166,109$0.133$0.135$0.122$0.124Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · AMEX:AEON · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.123-0.001-1.0%$0.133$0.135$0.1221,166,109
$0.124+0.011+9.6%$0.115$0.133$0.1151,840,987
$0.113-0.027-19.4%$0.156$0.156$0.1077,407,638
$0.141-0.012-8.0%$0.152$0.163$0.141543,569
$0.153-0.006-3.6%$0.161$0.170$0.153785,920
$0.159-0.013-7.4%$0.170$0.182$0.159247,784
$0.171-0.008-4.4%$0.180$0.182$0.170201,341
$0.179-0.003-1.4%$0.181$0.184$0.171229,135
$0.182+0.006+3.4%$0.180$0.185$0.166518,742
$0.176+0.018+11.3%$0.160$0.180$0.151900,142
$0.158-0.051-24.4%$0.219$0.219$0.1272,678,300
$0.209-0.003-1.4%$0.216$0.227$0.2096,550,800
$0.212-0.061-22.3%$0.275$0.275$0.2111,081,300
$0.273-0.001-0.4%$0.277$0.299$0.270323,900
$0.274-0.020-6.8%$0.284$0.290$0.270774,400
$0.294+0.030+11.4%$0.264$0.310$0.2641,339,500
$0.264+0.016+6.5%$0.249$0.269$0.244728,300
$0.248+0.008+3.3%$0.240$0.255$0.240139,800
$0.2400.0000.0%$0.235$0.250$0.235108,000
$0.240+0.006+2.6%$0.235$0.243$0.231198,900
$0.234-0.006-2.5%$0.237$0.240$0.233112,800
$0.240+0.008+3.4%$0.236$0.250$0.236145,700
$0.232+0.001+0.4%$0.238$0.241$0.220307,900
$0.231-0.001-0.4%$0.241$0.249$0.231459,000
$0.232-0.011-4.5%$0.236$0.248$0.231240,500
$0.243+0.014+6.1%$0.232$0.252$0.231391,400
$0.229-0.001-0.4%$0.230$0.241$0.2251,127,100
$0.230-0.016-6.5%$0.242$0.250$0.2251,289,100
$0.246-0.030-10.9%$0.274$0.284$0.2431,077,700
$0.276-0.034-11.0%$0.310$0.319$0.2761,618,500
$0.310-0.001-0.3%$0.312$0.324$0.2921,133,900
$0.311+0.021+7.2%$0.293$0.333$0.2852,916,200
$0.290+0.020+7.4%$0.264$0.295$0.2642,259,200
$0.270-0.009-3.2%$0.280$0.280$0.2491,740,900
$0.279-0.011-3.8%$0.300$0.300$0.2603,233,700
$0.290-0.010-3.3%$0.300$0.334$0.2776,638,000
$0.300+0.041+15.8%$0.321$0.419$0.240116,174,700
$0.259-0.003-1.1%$0.263$0.265$0.255194,900
$0.262-0.002-0.8%$0.261$0.270$0.260310,700
$0.264+0.004+1.5%$0.262$0.271$0.258565,200
$0.260-0.004-1.5%$0.265$0.269$0.255561,700
$0.264+0.002+0.8%$0.268$0.285$0.2601,282,500
$0.262+0.008+3.1%$0.258$0.265$0.252398,500
$0.254+0.011+4.5%$0.255$0.260$0.243661,800
$0.243-0.003-1.2%$0.254$0.267$0.2402,090,600
$0.246-0.011-4.3%$0.244$0.250$0.2321,467,500
$0.257-0.009-3.4%$0.267$0.277$0.2511,512,600
$0.266-0.020-7.0%$0.278$0.278$0.2512,083,400
$0.286-0.041-12.5%$0.326$0.345$0.2526,189,500
$0.327+0.037+12.8%$0.298$0.380$0.29031,010,500
$0.290+0.059+25.5%$0.296$0.354$0.280203,622,400
$0.231-0.004-1.7%$0.248$0.248$0.231470,300
$0.235-0.006-2.5%$0.245$0.245$0.230156,000
$0.241-0.014-5.5%$0.258$0.276$0.240758,600
$0.255-0.016-5.9%$0.279$0.279$0.250374,100
$0.271-0.006-2.2%$0.272$0.280$0.268194,500
$0.277-0.019-6.4%$0.283$0.287$0.263363,800
$0.296-0.018-5.7%$0.308$0.310$0.286506,200
$0.314+0.020+6.8%$0.299$0.316$0.2801,107,500
$0.294+0.042+16.7%$0.254$0.314$0.2524,701,200
$0.252+0.040+18.9%$0.211$0.253$0.2114,048,500
$0.212+0.015+7.6%$0.203$0.330$0.19040,763,600
$0.197+0.005+2.6%$0.201$0.202$0.190956,900
$0.192-0.001-0.5%$0.192$0.207$0.1801,722,300
$0.193-0.005-2.5%$0.205$0.208$0.1772,239,000

Splits

1 split · AMEX:AEON · every price before a split is adjusted for it

DayRatioWhat
1-for-72Consolidation
Ticker
NYSE American:AEON
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NYSE American
Currency
USD

What changed lately

Latest news

All AEON Biopharma, Inc. news

AEON Biopharma, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
15 in the last 12 months · 23 in all · newest Nov 9, 2026 · oldest 2024
Decks
16 decks · latest October 2026

Where AEON Biopharma, Inc. is listed

ListingExchangeCountryCurrency
NYSE American:AEON · Home listing · This pageNYSE AmericanUnited StatesUSD
BOATS:AEONBOATSUnited StatesUSD

Cash and shares

May 14, 2026 · AEON Biopharma — Investor Presentation (May 2026)

Cash
$1.5 million

The slide these figures come from

Valuation

Price/book 3.0× against a median of 1.2×: 7th lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$4.15M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
3.0×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
1.04

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
AEON Biopharma, Inc. · AMEX:AEONUS$7.27M−US$4.15Mn/an/an/a3.0×n/a0.0×1.04
Annexin Pharmaceuticals AB · OMXSTO:ANNXUS$7.59MUS$6.18Mn/an/an/a6.3×n/a0.0×n/a
Solvonis Therapeutics PLC · LSE:SVNSUS$7.57MUS$6.80Mn/an/an/a1.2×n/a0.0×n/a
Vistagen Therapeutics, Inc. · NASDAQ:VTGNUS$7.56M−US$11.87Mn/a−5.0×n/a0.5×n/a0.0×1.47
Noxopharm Ltd. · ASX:NOXUS$7.52MUS$10.36Mn/a11.0×n/an/a−312.2%n/an/a
Ascelia Pharma AB · OMXSTO:ACEUS$7.30MUS$3.63Mn/an/an/a0.8×n/a0.0×n/a
Pila Pharma AB · OMXSTO:PILAUS$7.01MUS$6.70Mn/an/an/a4.5×n/a0.0×n/a
Cadrenal Therapeutics, Inc. · NASDAQ:CVKDUS$7.01MUS$3.95Mn/an/an/a2.4×n/a0.0×1.60
Ensysce Biosciences, Inc. · NASDAQ:ENSCUS$7.00M−US$22.51Mn/a−3.6×n/a0.3×n/a0.0×1.28
Arctic Bioscience AS · OSL:ABSUS$7.00MUS$11.38Mn/a2.8×n/a0.4×−102.3%0.3×n/a
Alaunos Therapeutics, Inc. · NASDAQ:TCRTUS$6.99MUS$6.37Mn/a2,124×n/a7.2×n/a0.0×0.90
Median of the othersUS$7.16MUS$6.27M2.8×1.2×−207.2%0.0×1.38

Forecasts

1 strong buy · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.

Price target
1.82 USD · Analysts' mean
EPS, year to Dec 2026
-0.45 · 3 analysts

Team and board

Officers

OfficerRole
Rob BancroftPresident & CEO
John BencichChief Financial Officer -
Alex WilsonChief Legal & Strategy Officer, Secretary
Chad OhChief Medical Officer
Jennifer SyChief Accounting Officer
Paul LeeChief Regulatory Officer

Board

DirectorRole
Jost FischerChairman and Board Member
Eric CarterBoard Member
Marc ForthBoard Member
Rob BancroftPresident & CEO
Robert PalmisanoBoard Member
Shawn ParkBoard Member
Shelley ThunenBoard Member

Events

QuarterResultsShare move
Q3 2026Nov 16, 2026 · After close−19.4%
Q2 2026Aug 12, 2026 · After close−1.4%
Q1 2026May 14, 2026 · After close−9.9%
Q3 2025Nov 14, 2025 · Before open−3.7%
Q2 2025Aug 12, 2025 · After close+16.1%
Q1 2025May 14, 2025−1.8%
Q4 2024Mar 24, 2025+0.1%
Q3 2024Nov 13, 2024 · After close−11.3%
Q2 2024Aug 12, 2024 · After close−1.0%
Q1 2024May 14, 2024 · After close−3.1%
All 15 quarters
QuarterResultsShare move
Q4 2023Mar 29, 2024 · After close−36.0%
Q3 2023Nov 13, 2023 · Before open−1.2%
Q2 2023Aug 30, 2023+32.8%
Q1 2023May 31, 2023−0.7%
Q3 2021Oct 4, 2021

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (October 2026)Investor deck33 slidesOctober 2026
Investor Presentation (August 2026)Investor deck31 slidesAugust 2026
Investor Presentation (May 2026)Investor deck31 slidesMay 14, 2026
Investor Presentation (January 2026)Investor deck30 slidesJan 12, 2026
Investor Presentation (December 2025)Investor deck26 slidesDec 4, 2025
Investor Presentation (September 2025)Investor deck24 slidesSep 8, 2025
Aegis Capital Healthcare Conference May 2025Conference14 slidesMay 20, 2025
Investor Presentation (March 2025)Investor deck17 slidesMar 10, 2025
Investor Presentation (October 2024)Investor deck25 slidesOct 7, 2024
Investor Presentation (August 2024)Investor deck26 slidesAug 6, 2024
All 16 decks
DeckKindSlidesDate
Investor Presentation (October 2023)Investor deck34 slidesOct 19, 2023
Technical Presentation (October 2023)Technical21 slidesOct 19, 2023
Priveterra Acquisition — SPAC Merger (July 2023)SPAC merger35 slidesJul 24, 2023
Priveterra Acquisition — SPAC Merger (May 2023)SPAC merger48 slidesMay 24, 2023
Priveterra Acquisition — SPAC Merger (February 2023)SPAC merger41 slidesFeb 24, 2023
SPAC Merger (December 2022)SPAC merger37 slidesDecember 2022

Open Decks

Financings

RaiseDate
Public offering of underwritten public offering with milestone warrants
Closed: US$15.3M raised · US$0.3221 a share · one two-year milestone warrant (exercise price $0.3221) and one five-year milestone… · Lake Street Capital Markets, LLC +1
Dealers: Lake Street Capital Markets, LLC (lead), Laidlaw & Company (UK) Ltd.
Use of proceeds: Cash runway into the first quarter of 2027, supporting advancement of the ABP-450 development program
Aug 12, 2026
Private placement of pIPE financing
Tranche closed: US$1.79M raised
Use of proceeds: Uninterrupted execution of the analytical program and acceleration of ABP-450 biosimilar development
Jan 21, 2026

Open Financings · Read by 6ix AI from the company's releases

IPO

Went public as Priveterra Acquisition Corp., a blank check company (SPAC). Priced at US$10.00 a unit on Feb 8, 2021.

Price
US$10.00 a unit
Units offered
24,000,000 units
Offering size
US$240 million
Underwriters' option
Up to 3,600,000 more units
Listing
PMGMU on the Nasdaq Capital Market
Underwriters
Wells Fargo Securities, Guggenheim Securities, Odeon Capital Group, LLC · In the order on the cover
Units delivered
On or about Feb 11, 2021

Steps

StepWhen
Draft sent to the SEC in confidenceDec 23, 2020
Filed publiclyJan 21, 2021
Amended onceJan 29, 2021
Shares registered with an exchangeFeb 8, 2021
Declared effective by the SECFeb 8, 2021
Final prospectus, with the priceFeb 11, 2021

Open IPO · From the cover of the final prospectus (424B4) filed Feb 11, 2021

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue00002.52M3.36M
Cost of revenue78.0K01.00K
Gross profit-78.0K2.52M3.36M
Research and development4.09M14.2M33.0M34.8M25.7M7.32M4.81M
Selling, general and administrative12.2M13.6M13.7M11.2M11.6M46.0M
Operating income-12.8M73.0M-348.1M-48.4M-1.94M-16.4M-54.0M
Depreciation and amortization78.0K97.0K99.0K68.0K3.00K875.0K1.26M
EBITDA-12.7M73.1M-348.0M-48.4M-1.93M-15.5M-52.7M
Interest expense15.0K7.47M
Income before tax-39.2M42.0M-384.6M-52.6M8.20M-32.9M145.7M
Income tax00029.0M15.0K14.6M
Net income-39.2M42.0M-384.6M-52.6M8.20M-32.9M172.9M
Earnings per share, basic-3.9577.74-744.83-0.3818.86-68.691,873.44
Earnings per share, diluted-3.9572.93-0.38

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash and equivalents3.01M13.0K5.16M9.75M497.4K20.2M6.32M
Short-term investments0105.4M
Receivables0267.0K
Current assets3.40M1.59M6.22M9.84M835.2K20.4M112.1M
Property, plant and equipment162.0K235.0K431.0K922.0K
Total assets5.56M3.14M6.84M10.8M276.9M21.2M114.4M
Accounts payable942.0K5.91M3.39M7.80M1.19M2.03M1.02M
Current liabilities6.90M14.1M13.0M82.6M834.6K4.20M17.5M
Long-term debt34.6M11.7M60.4M70.8M72.2M15.2M
Total debt35.7M13.0M278.0K131.5M86.9M72.2M30.0M
Total liabilities60.6M31.7M159.9M143.2M17.9M224.4M180.2M
Shareholders' equity-55.0M-28.6M-153.0M-287.5M-16.9M-208.3M-67.2M
Shares outstanding12.1M555.5K516.4K138.8M434.8K479.2K92.3K

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash from operations-17.3M-20.3M-47.8M-35.6M-1.49M-9.46M-44.7M
Capital spending-4.00K00-306.0K-170.0K-170.0K-1.69M
Free cash flow-17.3M-20.3M-47.8M-35.9M-28.6M-9.46M-46.4M
Cash from investing-4.00K-306.0K-276.0M-1.26M-117.3M
Cash from financing20.3M15.1M14.0M40.5M278.0M24.6M73.2M
Dividends paid-83.9M
Share buybacks0-64.0K
Change in cash2.99M-5.14M-4.59M4.62M497.4K13.8M-88.8M

Open Financials

Filings

FilingDateTypeFiled with
4 · Change in ownershipNov 20, 2026Insider tradeSEC
4 · Change in ownershipNov 20, 2026Insider tradeSEC
4 · Change in ownershipNov 20, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeNov 16, 2026Big-stake noticeSEC
10-Q · Quarterly reportNov 16, 2026Quarterly reportSEC
8-K · Current reportNov 16, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeNov 13, 2026Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedNov 10, 2026Big-stake noticeSEC
4 · Change in ownershipNov 10, 2026Insider tradeSEC
424B3 · ProspectusNov 3, 2026Offer documentSEC
Show 200 filings
FilingDateTypeFiled with
8-K · Current reportNov 3, 2026Material contractSEC
DEF 14A · Proxy statementOct 26, 2026Meeting noticeSEC
8-K · Current reportOct 23, 2026Current reportSEC
PRE 14A · Preliminary proxy statementOct 13, 2026Meeting noticeSEC
8-K · Current reportSep 30, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeAug 21, 2026Big-stake noticeSEC
4 · Change in ownershipAug 21, 2026Insider tradeSEC
3 · Initial statement of ownershipAug 21, 2026Insider tradeSEC
10-Q · Quarterly reportAug 12, 2026Quarterly reportSEC
8-K · Current reportAug 12, 2026ResultsSEC
8-K · Current reportAug 3, 2026Current reportSEC
8-K · Current reportJul 23, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeJul 21, 2026Big-stake noticeSEC
8-K · Current reportJul 15, 2026Material contractSEC
424B4 · ProspectusJul 15, 2026Offer documentSEC
EFFECT · Notice that a registration is effectiveJul 14, 2026Other filingsSEC
S-1MEF · Registration of more shares for the same offeringJul 13, 2026Offer documentSEC
S-1/A · Registration statement, amendedJul 9, 2026Offer documentSEC
S-1 · Registration statementJul 8, 2026Offer documentSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
8-K · Current reportJun 17, 2026Meeting outcomeSEC
DRS · Draft registration statementMay 29, 2026Offer documentSEC
8-K · Current reportMay 14, 2026Current reportSEC
10-Q · Quarterly reportMay 14, 2026Quarterly reportSEC
8-K · Current reportMay 14, 2026ResultsSEC
ARS · Annual report to shareholdersApr 29, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 29, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 29, 2026Meeting noticeSEC
4 · Change in ownershipApr 3, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 3, 2026Insider tradeSEC
8-K · Current reportApr 3, 2026Current reportSEC
S-8 · Registration statement for employee plansMar 30, 2026Offer documentSEC
10-K · Annual reportMar 30, 2026Annual reportSEC
8-K · Current reportMar 30, 2026ResultsSEC
4 · Change in ownershipMar 11, 2026Insider tradeSEC
8-K · Current reportMar 9, 2026Management or board changeSEC
4 · Change in ownershipMar 5, 2026Insider tradeSEC
4 · Change in ownershipMar 5, 2026Insider tradeSEC
4 · Change in ownershipFeb 19, 2026Insider tradeSEC
424B3 · ProspectusFeb 18, 2026Offer documentSEC
EFFECT · Notice that a registration is effectiveFeb 18, 2026Other filingsSEC
CORRESP · Letter to the SECFeb 12, 2026Other filingsSEC
UPLOAD · Letter from the SECFeb 12, 2026Other filingsSEC
S-3 · Registration statementFeb 9, 2026Offer documentSEC
3 · Initial statement of ownershipJan 29, 2026Insider tradeSEC
SCHEDULE 13D · Big-stake noticeJan 29, 2026Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedJan 29, 2026Big-stake noticeSEC
8-K · Current reportJan 21, 2026Management or board changeSEC
8-K · Current reportJan 12, 2026Current reportSEC
DEF 14A · Proxy statementDec 29, 2025Meeting noticeSEC
PRE 14A · Preliminary proxy statementDec 19, 2025Meeting noticeSEC
8-K · Current reportDec 15, 2025Material contractSEC
8-K · Current reportDec 4, 2025Current reportSEC
DEFA14A · Additional proxy materialNov 14, 2025Meeting noticeSEC
10-Q · Quarterly reportNov 14, 2025Quarterly reportSEC
8-K · Current reportNov 14, 2025ResultsSEC
DEFA14A · Additional proxy materialNov 13, 2025Meeting noticeSEC
8-K · Current reportNov 13, 2025Material contractSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 14, 2025Big-stake noticeSEC
8-K · Current reportSep 8, 2025Current reportSEC
10-Q · Quarterly reportAug 12, 2025Quarterly reportSEC
8-K · Current reportAug 12, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 9, 2025Big-stake noticeSEC
424B5 · ProspectusJun 16, 2025Offer documentSEC
8-K · Current reportJun 13, 2025Meeting outcomeSEC
10-Q/A · Quarterly report, amendedJun 11, 2025Quarterly reportSEC
10-K/A · Annual report, amendedJun 11, 2025Annual reportSEC
DEFR14AJun 11, 2025Meeting noticeSEC
SCHEDULE 13G · Big-stake noticeMay 30, 2025Big-stake noticeSEC
4 · Change in ownershipMay 23, 2025Insider tradeSEC
4 · Change in ownershipMay 23, 2025Insider tradeSEC
4 · Change in ownershipMay 23, 2025Insider tradeSEC
4 · Change in ownershipMay 23, 2025Insider tradeSEC
4 · Change in ownershipMay 23, 2025Insider tradeSEC
4 · Change in ownershipMay 23, 2025Insider tradeSEC
4 · Change in ownershipMay 23, 2025Insider tradeSEC
4 · Change in ownershipMay 23, 2025Insider tradeSEC
4 · Change in ownershipMay 23, 2025Insider tradeSEC
4 · Change in ownershipMay 21, 2025Insider tradeSEC
8-K · Current reportMay 20, 2025Current reportSEC
4 · Change in ownershipMay 16, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
S-8 · Registration statement for employee plansMay 14, 2025Offer documentSEC
10-Q · Quarterly reportMay 14, 2025Quarterly reportSEC
8-K · Current reportMay 14, 2025ResultsSEC
4 · Change in ownershipMay 1, 2025Insider tradeSEC
3 · Initial statement of ownershipMay 1, 2025Insider tradeSEC
ARS · Annual report to shareholdersApr 29, 2025Annual reportSEC
DEF 14A · Proxy statementApr 29, 2025Meeting noticeSEC
8-K · Current reportApr 25, 2025Current reportSEC
8-K · Current reportApr 21, 2025Management or board changeSEC
8-K · Current reportApr 8, 2025Management or board changeSEC
8-K · Current reportMar 27, 2025Management or board changeSEC
10-K · Annual reportMar 24, 2025Annual reportSEC
8-K · Current reportMar 24, 2025ResultsSEC
SCHEDULE 13G · Big-stake noticeMar 10, 2025Big-stake noticeSEC
8-K · Current reportMar 10, 2025Current reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedMar 7, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMar 3, 2025Big-stake noticeSEC
UPLOAD · Letter from the SECFeb 28, 2025Other filingsSEC
8-K · Current reportFeb 24, 2025Meeting outcomeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
8-K · Current reportFeb 7, 2025Current reportSEC
DEF 14A · Proxy statementJan 23, 2025Meeting noticeSEC
SCHEDULE 13D · Big-stake noticeJan 22, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeJan 13, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeJan 13, 2025Big-stake noticeSEC
PRE 14A · Preliminary proxy statementJan 13, 2025Meeting noticeSEC
SCHEDULE 13G · Big-stake noticeJan 8, 2025Big-stake noticeSEC
8-K · Current reportJan 7, 2025Material contractSEC
424B5 · ProspectusJan 7, 2025Offer documentSEC
8-K · Current reportJan 6, 2025Current reportSEC
424B5 · ProspectusJan 6, 2025Offer documentSEC
8-K · Current reportDec 20, 2024Current reportSEC
SC 13G · Big-stake noticeNov 14, 2024Big-stake noticeSEC
424B3 · ProspectusNov 13, 2024Offer documentSEC
10-Q · Quarterly reportNov 13, 2024Quarterly reportSEC
8-K · Current reportNov 13, 2024ResultsSEC
8-K · Current reportOct 7, 2024Current reportSEC
4/A · Change in ownership, amendedSep 10, 2024Insider tradeSEC
4 · Change in ownershipSep 4, 2024Insider tradeSEC
4 · Change in ownershipSep 4, 2024Insider tradeSEC
4 · Change in ownershipSep 4, 2024Insider tradeSEC
4 · Change in ownershipSep 4, 2024Insider tradeSEC
4 · Change in ownershipSep 4, 2024Insider tradeSEC
4 · Change in ownershipSep 4, 2024Insider tradeSEC
4 · Change in ownershipSep 4, 2024Insider tradeSEC
4 · Change in ownershipSep 4, 2024Insider tradeSEC
EFFECT · Notice that a registration is effectiveAug 22, 2024Other filingsSEC
424B5 · ProspectusAug 21, 2024Offer documentSEC
CORRESP · Letter to the SECAug 20, 2024Other filingsSEC
UPLOAD · Letter from the SECAug 19, 2024Other filingsSEC
S-3 · Registration statementAug 14, 2024Offer documentSEC
424B3 · ProspectusAug 12, 2024Offer documentSEC
10-K/A · Annual report, amendedAug 12, 2024Annual reportSEC
8-K · Current reportAug 12, 2024ResultsSEC
10-Q · Quarterly reportAug 12, 2024Quarterly reportSEC
8-K · Current reportAug 6, 2024Current reportSEC
EFFECT · Notice that a registration is effectiveAug 6, 2024Other filingsSEC
424B3 · ProspectusAug 5, 2024Offer documentSEC
CORRESP · Letter to the SECAug 2, 2024Other filingsSEC
144 · Notice of proposed saleJul 29, 2024Other filingsSEC
CORRESP · Letter to the SECJul 23, 2024Other filingsSEC
S-1/A · Registration statement, amendedJul 23, 2024Offer documentSEC
UPLOAD · Letter from the SECJul 16, 2024Other filingsSEC
8-K · Current reportJul 9, 2024Current reportSEC
CORRESP · Letter to the SECJul 9, 2024Other filingsSEC
UPLOAD · Letter from the SECJun 28, 2024Other filingsSEC
UPLOAD · Letter from the SECJun 27, 2024Other filingsSEC
8-K · Current reportJun 14, 2024Meeting outcomeSEC
CORRESP · Letter to the SECMay 31, 2024Other filingsSEC
S-1/A · Registration statement, amendedMay 31, 2024Offer documentSEC
3 · Initial statement of ownershipMay 24, 2024Insider tradeSEC
8-K · Current reportMay 16, 2024Management or board changeSEC
10-Q · Quarterly reportMay 14, 2024Quarterly reportSEC
8-K · Current reportMay 14, 2024ResultsSEC
ARS/A · Annual report to shareholders, amendedMay 14, 2024Annual reportSEC
DEFA14A · Additional proxy materialMay 14, 2024Meeting noticeSEC
10-K/A · Annual report, amendedMay 14, 2024Annual reportSEC
8-K · Current reportMay 3, 2024Current reportSEC
8-K · Current reportMay 3, 2024Current reportSEC
UPLOAD · Letter from the SECApr 30, 2024Other filingsSEC
ARS · Annual report to shareholdersApr 29, 2024Annual reportSEC
DEF 14A · Proxy statementApr 29, 2024Meeting noticeSEC
25-NSEApr 29, 2024Other filingsSEC
3 · Initial statement of ownershipApr 18, 2024Insider tradeSEC
PRE 14A · Preliminary proxy statementApr 17, 2024Meeting noticeSEC
8-K · Current reportApr 17, 2024Material contractSEC
4/A · Change in ownership, amendedApr 16, 2024Insider tradeSEC
8-K · Current reportApr 15, 2024Current reportSEC
4 · Change in ownershipApr 12, 2024Insider tradeSEC
CORRESP · Letter to the SECApr 2, 2024Other filingsSEC
S-1/A · Registration statement, amendedApr 2, 2024Offer documentSEC
S-8 · Registration statement for employee plansApr 1, 2024Offer documentSEC
8-K · Current reportMar 29, 2024Current reportSEC
10-K · Annual reportMar 29, 2024Annual reportSEC
10-Q/A · Quarterly report, amendedMar 29, 2024Quarterly reportSEC
8-K · Current reportMar 29, 2024ResultsSEC
8-K · Current reportMar 28, 2024Material contractSEC
4 · Change in ownershipMar 26, 2024Insider tradeSEC
4 · Change in ownershipMar 21, 2024Insider tradeSEC
4 · Change in ownershipMar 21, 2024Insider tradeSEC
4 · Change in ownershipMar 21, 2024Insider tradeSEC

This page holds 200 of 370 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from AEON Biopharma, Inc.’s releases · as of Aug 12, 2026

Common shares
59,084,675
Fully diluted
59,084,675

Fully diluted

LineShares
Common shares59,084,675

Warrants and options

Lot
Warrants · expiry not stated

Share count over time

CountShares
Nov 22, 202659,084,675

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Dauntless Investment Group, LLC51.7M61.5%US$15.5MSep 30, 2026
Nantahala Capital Management, LLC4.4M5.2%US$1.3MSep 30, 2026
Ikarian Capital, LLC2.2M2.6%US$661KSep 30, 2026
Stonepine Capital Management, LLC2.13M2.5%US$638KSep 30, 2026
Boothbay Fund Management, LLC704K0.84%US$211KSep 30, 2026
Vanguard305K0.36%US$91,577Sep 30, 2026
DG Capital Management, LLC259K0.31%US$77,744Sep 30, 2026
Jane Street250K0.30%US$74,928Sep 30, 2026
Geode Capital95,3110.11%US$28,592Sep 30, 2026
Citadel55,6840.07%US$16,705Sep 30, 2026
All 27 holders
HolderSharesOf the companyValueAs of
Blue Owl Capital Holdings LP42,3530.05%US$12,706Sep 30, 2026
Susquehanna21,0180.02%US$6,305Sep 30, 2026
Formidable Asset Management, LLC20,0240.02%US$14,403Sep 30, 2026
Beacon Wealthcare LLC12,8560.02%US$3,857Sep 30, 2026
LPL Financial LLC11,5000.01%US$3,450Sep 30, 2026
XTX Topco Ltd11,0100.01%US$3,303Sep 30, 2026
BlackRock2,834<0.01%US$850Sep 30, 2026
Steward Partners Investment Advisory, LLC1,100<0.01%US$330Sep 30, 2026
Wolff Wiese Magana LLC567<0.01%US$171Sep 30, 2026
SBI Securities Co., Ltd.329<0.01%US$99Sep 30, 2026
Dupont Capital Management Corp170<0.01%US$51Sep 30, 2026
Morgan Stanley150<0.01%US$45Sep 30, 2026
GHP Investment Advisors, Inc.95<0.01%US$29Sep 30, 2026
Wells Fargo90<0.01%US$27Sep 30, 2026
Caitong International Asset Management Co., Ltd1<0.01%Sep 30, 2026
Danske Bank A/S1<0.01%Sep 30, 2026
Barclays1<0.01%Sep 30, 2026

Funds

HolderSharesOf the companyValueAs of
Vanguard Extended Market Index Fund90,5290.11%US$65,118Jun 30, 2026
Fidelity Extended Market Index Fund47,5350.06%US$35,970May 31, 2026
Fidelity Series Total Market Index Fund11,1920.01%US$8,469May 31, 2026
Fidelity Total Market Index Fund3,072<0.01%US$2,325May 31, 2026

Insider trades

TradeTradeSharesPriceValueDate
Wilson Alexander Blair
Officer: CLO, CSO and Corp Secretary
Buy135,706USD 0.13US$17,479Nov 20, 2026
Sy Jennifer
Officer: Chief Accounting Officer
Buy153,846USD 0.13US$19,985Nov 19, 2026
Bancroft Robert E.
Director, Officer: President and CEO
Buy152,333USD 0.13US$19,590Nov 19, 2026
Timothy P. Lynch
10% owner
Buy1,150,000USD 0.21US$242KAug 19, 2026

Big stakes

StakeStakeSharesDateFiling
Daewoong Co., Ltd.30.60%23.2MOct 30, 2026Schedule 13D
Timothy P. Lynch13.00%6.5MAug 19, 2026Schedule 13G
Nantahala Capital Management, LLC9.99%5.05MSep 30, 2026Schedule 13G
Ikarian Capital, LLC9.90%7.36MSep 30, 2026Schedule 13G
Stonepine Capital Management, LLC9.90%6.89MJul 15, 2026Schedule 13G
Chernett Jorey9.90%1.13MMay 27, 2025Schedule 13G
Dauntless Investment Group, LLC9.70%108KFeb 26, 2025Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Shelley Thunen
Other companies: LENZ Therapeutics, Inc. (Member · Since at least Mar 21, 2024); RxSight, Inc. (See remarks · Jul 29, 2021 – Apr 14, 2025 · Past)
Director · Since at least Jul 21, 2023
James Lightman
Other companies: Wright Medical Group N.V (SVP, General Counsel & Sec · Oct 1, 2015 – Nov 11, 2020 · Past)
Director · Feb 8, 2021 – Feb 8, 2021 · Past
Robert J. Palmisano
Other companies: RxSight, Inc. (Director · Since at least Jun 18, 2026)
Board Member · Since at least Jun 22, 2026
Vikram Malik
Other companies: Evolus, Inc. Common Stock (Director · Since at least Feb 7, 2018)
President, Director · Feb 8, 2021 – Feb 8, 2021 · Past
Alex WilsonChief Legal & Strategy Officer, Secretary · Since at least Jul 21, 2023
Chad OhChief Medical Officer · Since at least Jul 21, 2023
David MeredithChief Legal Officer&Secretary · Feb 8, 2021 – Feb 8, 2021 · Past
Eric CarterBoard Member · Since at least Jun 22, 2026
Jennifer SyChief Accounting Officer · Since at least Nov 5, 2026
John BencichChief Financial Officer - · Since at least Apr 3, 2026
All 16 people
PersonSeat
Jost FischerDirector · Since at least Mar 19, 2024
Marc ForthBoard Member · Since at least Nov 13, 2024
Paul LeeChief Regulatory Officer · Since at least Nov 5, 2026
Rob BancroftPresident and CEO, Director · Since at least Apr 29, 2025
Seongsoo ParkDirector · Apr 12, 2024 – Apr 12, 2024 · Past
Shawn ParkBoard Member · Since at least Nov 5, 2026

Open People

Log in to ask 6ix AI your own questions about AEON Biopharma, Inc.